The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2022-03-24
-Paragraph 118
-Subparagraph e
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 55
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_OtherCurrentLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]

+ References

+ Details

Name:	ifrs-full_OtherNoncurrentLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration Agreements, Development Milestone Payment

+ References

No definition available.

+ Details

Name:	sny_CollaborationAgreementsDevelopmentMilestonePayment
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration Agreements, Regulatory Milestone Payment

+ References

No definition available.

+ Details

Name:	sny_CollaborationAgreementsRegulatoryMilestonePayment
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration Agreements, Upfront Payment

+ References

No definition available.

+ Details

Name:	sny_CollaborationAgreementsUpfrontPayment
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Commitments Related To Milestone Payments For Projects Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Disclosure Of Principal Agreements [Line Items]

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfPrincipalAgreementsLineItems
Namespace Prefix:	sny_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities

+ References

No definition available.

+ Details

Name:	sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage Of Development Costs Arising From Commercial Operations

+ References

No definition available.

+ Details

Name:	sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations
Namespace Prefix:	sny_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Net Sales Arising From Commercial Operations

+ References

No definition available.

+ Details

Name:	sny_PercentageOfNetSalesArisingFromCommercialOperations
Namespace Prefix:	sny_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Profits Arising From Commercial Operations

+ References

No definition available.

+ Details

Name:	sny_PercentageOfProfitsArisingFromCommercialOperations
Namespace Prefix:	sny_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sny_MajorFinancialLiabilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_GeographicalAreasAxis=sny_MajorTerritoriesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_GeographicalAreasAxis=sny_OtherTerritoriesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_GeographicalAreasAxis=country_CN
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details) - EUR (€) € in Millions				1 Months Ended		3 Months Ended	6 Months Ended
	Jul. 17, 2023	Apr. 11, 2023	Apr. 09, 2023	Nov. 30, 2022	Mar. 31, 2017	Sep. 30, 2019	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Disclosure Of Principal Agreements [Line Items]
Other non-current liabilities							€ 2,070	€ 519	€ 422
Other intangible assets excluding software
Disclosure Of Principal Agreements [Line Items]
Acquisitions and other increases							1,757
Antibodies Collaboration Agreement \| AstraZeneca
Disclosure Of Principal Agreements [Line Items]
Collaboration agreements, upfront payment					€ 120
Collaboration agreements, development milestone payment						€ 30
Collaboration agreements, regulatory milestone payment				€ 25
Commitments related to potential milestone payments for projects under collaboration agreements							€ 440
Percentage of development costs arising from commercial operations							50.00%
Antibodies Collaboration Agreement \| AstraZeneca \| Other intangible assets excluding software
Disclosure Of Principal Agreements [Line Items]
Acquisitions and other increases		€ 1,632	€ 1,632
Antibodies Collaboration Agreement \| AstraZeneca \| Other intangible assets excluding software \| Major financial liability
Disclosure Of Principal Agreements [Line Items]
Acquisitions and other increases	€ 65
Antibodies Collaboration Agreement \| AstraZeneca \| Major territories
Disclosure Of Principal Agreements [Line Items]
Percentage of profits arising from commercial operations							50.00%
Antibodies Collaboration Agreement \| AstraZeneca \| Other territories
Disclosure Of Principal Agreements [Line Items]
Percentage of net sales arising from commercial operations							25.00%
Antibodies Collaboration Agreement \| AstraZeneca \| China
Disclosure Of Principal Agreements [Line Items]
Percentage of profits arising from commercial operations							50.00%
Antibodies Collaboration Agreement \| Swedish Orphan Biovitrum AB
Disclosure Of Principal Agreements [Line Items]
Other non-current liabilities			1,609				€ 1,613
Other current liabilities			€ 23
Antibodies Collaboration Agreement \| Swedish Orphan Biovitrum AB \| Major financial liability
Disclosure Of Principal Agreements [Line Items]
Increase through remeasurement of financial liability	€ 50